Abstract: The present disclosure provides methods of treating myeloproliferative neoplasm in a subject in need thereof, the method comprising administering to the subject a compound chosen from angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and renin inhibitors, wherein the compound is administered in an amount effective to treat the myeloproliferative neoplasm in the subject. Also disclosed herein are methods of stabilizing megakaryocytes, at least one hematopoietic growth factor and/or at least one serum amyloid A (SAA) in a patient having a myeloproliferative neoplasm, the method comprising administering to the patient a compound chosen from ACE inhibitors, ARBs, and renin inhibitors, wherein the compound is administered in an amount effective to stabilize megakaryocytes, the at least one hematopoietic growth factor and/or the at least one serum amyloid A (SAA) in the patient.

Abstract: Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade.

Abstract: Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade.